Pfizer has submitted the results of research on the effects of its Kovid-19 vaccine on children to the US Food and Drug Administration (FDA), but the vaccine may not be available until November.
The company said on Tuesday that it had provided health regulators with data from a recent study on the vaccination of children between the ages of five and 11. Officials had earlier said they would request the FDA for permission to use the vaccines in the coming week.
After the company files an application, US regulatory and public health officials will review the evidence and consult their advisory committees at public meetings to determine whether the vaccines are safe and sufficiently effective. Vaccines can be recommended for children only after all the criteria are met.
Vaccines won’t be available until Thanksgiving
An official with knowledge of the process said the process means the vaccines probably won’t be available before ‘Thanksgiving’, but if the FDA acts swiftly, the vaccines are expected to be available in early November.
The drugmaker and its subsidiary, Germany’s BioNTech, said they could request emergency permission to use their vaccine for children aged five to 11 years “in the coming week”. The company also plans to provide data to the European Medicines Agency and other regulators.
The Pfizer vaccine is currently available to people 12 years of age and older. The Centers for Disease Control and Prevention said that about 10 crore people have been vaccinated against Pfizer.
Gurugram: Husband gets GPS device installed in car to track doctor wife, case registered
Odisha government will provide financial assistance of 50,000 to the families of those who died of Kovid-19, the state government announced